Paliperidone palmitate
| Clinical data | |
|---|---|
| Trade names | Invega Hafyera, Invega Sustenna, Invega Trinza, others |
| Other names | PP; PP1M; PP3M; PP6M; JNS-010; RO-92670; RO92670 |
| MedlinePlus | a607005 |
| License data | |
| Routes of administration | Intramuscular |
| Drug class | Atypical antipsychotic |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.208.402 |
| Chemical and physical data | |
| Formula | C39H57FN4O4 |
| Molar mass | 664.907 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Paliperidone palmitate (PP), sold under the brand names Invega Sustenna, Xeplion, Shansida (Chinese: 善思达), Erzofri and Psokadron for the once‑monthly formulation, and as Invega Trinza/Trevicta (three‑monthly) and Invega Hafyera/Byannli (six‑monthly), is a long-acting injectable atypical antipsychotic of the benzisoxazole class, used in the treatment of schizophrenia and schizoaffective disorder. The original product was developed by Janssen Pharmaceuticals, Inc. (Johnson & Johnson), which continues to manufacture most of the branded versions worldwide. It is an antipsychotic ester – specifically the palmitate ester of paliperidone – and acts as a long-lasting form of paliperidone. Paliperidone palmitate is formulated as an aqueous suspension, has a strong smell similar to alcohol, and is administered by intramuscular injection into deltoid or gluteal muscle once every 1, 3, or 6 months depending on the formulation. A formulation for injection once every 6 months is also pending regulatory approval as of September 2021.